Tuesday, 21st June Advances in Neuroblastoma Research Congress 2016

• Not available at time of print - Neal Rosen

• The BRIP1/FANCJ DNA helicase is a druggable 17q driver oncogene involved in G-quadruplex induced replicative stress resistance in neuroblastoma - Suzanne Vanhauwaert
• MLL1 and JMJD3 regulate neuroblastoma cancer stem cells - Saurabh Agarwal
• Sensing mutant ALK: capicua and ETV5 as executors of aberrant ALK-driven MAPK signaling in neuroblastoma - Liselot Mus
• TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors - Jan Koster

• INRG Data Commons – A User Journey - Samuel L Volchenboum

• Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional deregulation in unfavorable neuroblastomas - Frank Westermann
• Dissecting neuroblastoma specific regulatory networks through epigenome mapping and transcriptional profiling of neuroblastoma and neural crest cell lines - Isabelle Janoueix-Lerosey
• The histone chaperone CHAF1A promotes tumorigenesis and opposes neuroblastoma differentiation via metabolic reprogramming. - Jason Shohet
• The TBX2 super-enhancer marked transcription factor on 17q is overexpressed in neuroblastoma and infers poor prognosis - Bieke Decaesteker
• The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex. - Shana Claeys
• Combination therapy with the bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce LIN28B gene and N-Myc protein expression and suppress neuroblastoma progression - Tao Liu

• High frequency of mutations in chromatin remodeling genes in neuroblastoma - Angela Bellini
• Identification of spliceosomal components as novel therapeutic targets for the treatment of high-risk, MYCN-driven neuroblastoma - Melinda Halasz
• The orally bioavailable small molecule CDK9 inhibitors CYC065 and CCT68127 are potent inhibitors of MYCN transcription - Evon Poon
• Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-NMYC neuroblastoma mouse model - Paul J Wood
• A novel antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in models of neuroblastoma - Renata Sano
• Oncolytic herpes Simplex-1 virotherapy augments chimeric antigen receptor T-Cell (CAR-T) therapy in Neuroblastomas - Kellie Haworth

• Prenatal stress increases NB tumorigenicity in TH-MYCN mice. - Joanna Kitlinska
• Identifying mechanisms of neuroblastoma tumorigenesis using single cell transcriptomics - Daniel R Carter
• ARID1A and ARID1B mutations in the Swi/Snf BAF chromatin remodeling complex drive poor outcome neuroblastoma - Michael Hogarty
• Identification of somatic mutations determining the neuroblastoma phenotype - Matthias Fischer
• MYCN and HDAC5 transcriptionally repress CD9 to trigger an invasion-metastasis cascade in neuroblastoma - Hedi Deubzer
• MYCN amplified neuroblastomas require TEAD4 to orchestrate transcriptional programs, exposing a therapeutic vulnerability - Gonzalo Lopez

• Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG) - Steven G. DuBois
• Discordance in ¹²³I-MIBG (MIBG) and ¹⁸FDG positron emitting tomography (PET) scans after multimodality therapy for high-risk neuroblastoma: clinical implications - Shakeel Modak
• Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma - Yen-Lin Liu
• Towards a model for risk stratification of high-risk neuroblastoma. A report from the HR-NBL-1/SIOPEN study. - Daniel A Morgenstern
• Revisions to the International Neuroblastoma Response Criteria: A consensus statement from the NCI-Clinical Trials Planning Meeting - Julie R. Park
• Risk factors for outcome after relapse or progression of localized Neuroblastoma - Barbara Hero

Genetic heterogeneity and clonal evolution have been shown to play a role in progression of neuroblastoma. Recent data from other malignancies suggest that genetic heterogeneity might reflect not only evidence of competing clones, but also cooperating clonal events. This workshop will focus on neuroblastoma genetic heterogeneity, seeking to explore how recent and emerging technologies such as single cell studies and surrogate samples including circulating tumor DNA (ctDNA)  and disseminated/circulating tumor cells (DTC/CTC)  and can contribute to the understanding of the role of genetic heterogeneity and clonal evolution in tumor progression. While highlighting technical issues, challenges and pitfalls, the important questions of how these findings can be harnessed for clinical management of neuroblastoma patients will be further discussed.

• Single cells studies of the brain and its malignancies - Spyros Darmanis
• The biological and clinical relevance of tumoral heterogeneity and clonal evolution in high-risk neuroblastoma - John Maris
• Impact of bome marrow-derived disseminated neuroblastoma cells on the identification of the relapse seeding clone - M. Reza Abbasi
• Addressing tumor heterogeneity in NB - potential and challenges of liquid biopsies - Angelika Eggert
• Panel Discussion - Gudrun Schleiermacher

Risk stratification approaches that rely on robust clinical and biological prognostic factors have been used to predict outcome and tailor therapies for neuroblastoma patients for more than two decades. Current classification systems utilize clinical, histologic, and genetic factors to identify patients with low, intermediate, or high risk neuroblastoma. Recent advances have resulted in improved patient outcomes; however, long-term survival for high-risk patients remains < 50%. Furthermore, current prognostic factors do not predict which high-risk (HR) neuroblastoma patients will fail to achieve remission with current era therapies. There are many efforts aimed at prospectively identifying the subset of HR patients at highest risk of death, or “ultra-high risk (UHR) patients, “ for whom novel therapies may be indicated early on in the course of the disease. Currently there is no uniform definition for UHR and to date, no clinical or genetic determinant(s) reliably identify UHR patients. In this workshop we will highlight recent advances in the discovery of germline and somatic genomic alterations that may predict poor outcome or failure to respond to therapy in the setting of high-risk disease. The potential roles for gene expression signatures and detection of minimal residual disease will also be discussed. Following these presentations there will be a panel discussion to consider how to incorporate these novel prognostic factors into upfront clinical trials and how we may use genomic markers and minimum residual disease status together with current prognostic factors to further refine the next generation of risk classification systems.  

• Introduction, overview and goals - Meredith Irwin
• Can germline and somatic mutations (or rare variants) help us identify "ultra-high risk" neuroblastoma and predict patient outcomes? - Sharon Diskin
• Copy number profiles as prognostic marker for high-risk neuroblastoma patients - Katleen De Preter
• Molecular risk stratification of neuroblastoma patients - using RNA, DNA, or both? - Matthias Fischer
• Clinical impact and technical application of reverse transcriptase polymerase chain reaction to detect neuroblastoma RNAs in bone marrow and blood - Sue Burchill
• Panel Discussion - Meredith Irwin

• Common germline variants at MLF1 and CPZ loci associated with neuroblastoma susceptibility - Sharon J. Diskin
• Suppressing the expression of a single novel long noncoding RNA leads to neuroblastoma regression or eradication - Tao Liu
• Identification of new synthetic lethal genes in MYCN-amplified neuroblastoma cells - Shinichi Kiyonari
• A non-canonical tumor suppression pathway identified in neuroblastoma – A New Paradigm for Personalized Treatment and Prognosis - Zhi Xiong Chen
• Comprehensive analysis of neuroblastoma using high depth cancer gene panel sequencing - Ji Won Lee
• Cell lines (CLs) and patient derived xenografts (PDXs) established from post-mortem neuroblastoma samples display heterogeneity in sensitivity to chemotherapeutic agents commonly utilized in the treatment of high-risk neuroblastoma patients. - Michael M Song
• Enhancing ¹³¹I-mIBG radiation therapy with oncolytic HSV1716 and NAT gene therapy in high-risk neuroblastoma - Keri A Streby
• The CHK1 inhibitor CCT244747, alone and in combination with gemcitabine, is active against p53 deficient models of neuroblastoma resistant to chemotherapy. - Giuseppe Barone
• Engraftment following busulfan/melphalan (BuMel) high-dose chemotherapy for high-risk neuroblastoma. A report from the HR-NBL-1/SIOPEN trial. - Daniel A Morgenstern
• 131Iodine-metaiodobenzylguanidine (131I -MIBG) and autologous stem cell transplantation harvesting and hematological reconstitution in high-risk neuroblastoma patients. - Godelieve Tytgat
• Prognostic Factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN Trial. - Ruth Ladenstein
• Establishment of a reproducible methodology and results for molecular radiotherapy dosimetric assessment of¹⁷⁷Lu-DOTATATE in neuroblastoma - Matthew D Aldridge
• Phase I trial of perifosine monotherapy in patients with relapsed or refractory neuroblastoma - Hiroyuki Shichino
• Busulfan and melphalan pharmacokinetics in high-risk neuroblastoma patients treated on the HR-NBL1/SIOPEN trial - Gareth Veal
• Genomic profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma - Gudrun Schleiermacher
• High efficacy of the BCL-2 inhibitor venetoclax (ABT-199) in neuroblastoma and rational for combination therapy.- Laurel T. Bate-Eya
• Pharmacokinetics (PK) of 13-cis Retinoic Acid in COG Phase III Neuroblastoma Studies – Min Kang

• Impact of the involvement of the separate body regions in the modified Curie and the SIOPEN mIBG-scoring systems in patients with stage 4 neuroblastoma - Boris Decarolis
• Prognostic significance of imbalanced chromosomal alterations in primary and recurrent neuroblastoma - Alexander E. Druy
• ¹⁸F-Meta Fluorobenzyl Guanidine (MFBG) Positron Emission Tomography(PET) imaging in patients with Neuroblastoma and other Neuroendocrine Malignancies - Shakeel Modak
• ¹²⁴I-hu3F8 radioimmuno-positron emission tomography (PET) in patients with neuroblastoma and other GD2-positive malignancies: preliminary results on biodistribution, pharmacokinetics and tumor targeting - Shakeel Modak
• A High ALK expression is associated with an unfavorable histology in Neuroblastoma. - Atsuko Nakazawa
• Feasibility of applying F¹⁸-DOPA hybrid MR-PET to follow-up of neuroblastoma patients - Meng Yao Lu
• Co-expression network analysis reveals long non-coding RNA SNHG1 as a novel biomarker in neuroblastoma - Divya Sahu
• Post surgical 123I-MIBG SPECT/CT in neuroblastoma - Gudrun Schleiermacher
• High-risk neuroblastoma without MYCN amplification in patients between 12 and 18 months: Is there a hidden low-risk patient group? - Gudrun Schleiermacher
• The detection and quantification of neuroblastoma metastases in bone marrow using plasmids-targets as standards in QRT-PCR - Katarzyna Szewczyk
• Validation of image-defined risk factor (IDRF) assignment in patients with intermediate-risk neuroblastoma: a report from the Children’s Oncology Group study ANBL0531 - Clare J. Twist
• Epithelial to mesenchymal transition and minimal residual disease monitoring in neuroblastoma - Godelieve Tytgat
• Computer-assisted Curie scoring for Metaiodobenzylguanidine (mIBG) Scans in Patients with Neuroblastoma - Sam Volchenboum
• Lack of adaptive immunity markers is associated with early death amongst high-risk neuroblastomas. - Kristoffer von Stedingk
• High-MKI neuroblastomas - MYC-family-driven tumors with augmented expression of MYCN/MYC protein behaves more aggressively than Non-MYC-family-driven tumors: a report from the Children’s Oncology Group - Larry L Wang
• XPO1 is overabundant in patients with neuroblastoma at ultra-high-risk for treatment failure: rationale for refined diagnostic risk stratification and targeted therapy - Daniel Weiser
• Incidence of stage IV neuroblastoma patients 2-5 years of age was increased after the cessation of mass screening in Japan - Akihiro Yoneda
• Molecular Karyotyping in Neuroblastoma – time to stop G-banding. - Elise Young
• Neural stem cell-mediated enzyme/prodrug therapy for neuroblastoma: translation to the clinic - Clarke Anderson
• A comprehensive preclinical study of ALK inhibitors for the efficacious treatment of ALK^F1174L/MYCN-driven neuroblastoma - Giuseppe Barone
• The CHK1 inhibitor CCT244747, alone and in combination with gemcitabine, is active against p53 deficient models of neuroblastoma resistant to chemotherapy. - Giuseppe Barone
• High efficacy of the BCL-2 inhibitor venetoclax (ABT-199) in neuroblastoma and rational for combination therapy. - Laurel T. Bate-Eya
• Neuroblastoma drug response profiles are associated with gene expression profiles - Jeffrey Bond
• A high-throughput drug screening of FDA approved anti-cancer compounds suggests candidate tyrosine kinase inhibitors for repositioning in neuroblastoma therapy - Mario Capasso
• ITCC Biology: pre-clinical targeted drug development for high-risk pediatric cancers - Emmy Dolman
• Effects on tumor cells and the immune microenvironment may both contribute to the anti-tumor activities of DFMO in neuroblastoma pre-clinical models - Andrea Flynn
• Targeting NEDD8: a novel approach to treating neuroblastoma - Jennifer H Foster
• Targeting the polyamine pathway in combination with conventional chemotherapy for the treatment of childhood neuroblastoma - Laura D. Gamble
• Targeting cell cycle and transcriptional CDKs using Roniciclib leads to significant high cell death in MYCN/MYC-activated neuroblastoma cells - Sina Gogolin
• Identification of novel pathways and molecules able to down regulate oncogenes expression by in vitro drug screening approaches in neuroblastoma cells. - Mitsuteru Hiwatari
• Cell lines (CLs) and patient derived xenografts (PDXs) established from post-mortem neuroblastoma samples display heterogeneity in sensitivity to chemotherapeutic agents commonly utilized in the treatment of high-risk neuroblastoma patients. - Michael M Song
• Enhancing ¹³¹I-mIBG radiation therapy with oncolytic HSV1716 and NAT gene therapy in high-risk neuroblastoma - Keri A Streby
• Common germline variants at MLF1 and CPZ loci associated with neuroblastoma susceptibility - Sharon J. Diskin
• Mutational dynamics between primary and relapse neuroblastoma involve the Hippo/YAP1 pathway and genes relevant for epithelial-mesenchymal transition - Angelika Eggert
• Comprehensive analysis of neuroblastoma using high depth cancer gene panel sequencing - Ji Won Lee
• Suppressing the expression of a single novel long noncoding RNA leads to neuroblastoma regression or eradication - Tao Liu
• Long non-coding RNAs as novel components in the TP53 pathway - Dries Rombaut
• Genomic profiling in low and intermediate risk neuroblastoma to refine treatment stratification and improve patient outcome – LINES: a SIOPEN Trial - Gudrun Schleiermacher
• Genomic profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma - Gudrun Schleiermacher
• The chromatin associated protein JARID2 Is a novel LIN28B-Influenced target in neuroblastoma - Robert W Schnepp
• Loss of ATM function confers risk for advanced stage neuroblastoma but provides a therapeutic target for poly-ADP ribose polymerase inhibitors   - Masatoshi Takagi
• Investigation on the miRNA signature in retinoic acid-resistant neuroblastoma cells as novel therapeutic targets - Ya-Hui Tsai
• Integrated network analysis of G-quadruplex and replicative stress related genes as sources for neuroblastoma genomic instability - Christophe Van Neste
• The histone demethylase KDM5A regulates p53 function via a translation mechanism - Jun Yang
• Identification of non-invasive biomarkers for treatment response in neuroblastoma by circulating miRNA profiling - Alan Van Goethem
• Busulfan and melphalan pharmacokinetics in high-risk neuroblastoma patients treated on the HR-NBL1/SIOPEN trial - Gareth Veal
• Clinical follow-up of high-risk neuroblastoma patients receiving individualised 13-cis-retinoic acid based on pharmacological exposure as part of a national UK study - Gareth J Veal
• Providing information on clinical trials to parents of children with neuroblastoma: a novel liaison in a clinical nurse specialist role. - Daniel A Morgenstern
• Premature physeal closure following prolonged fenretinide administration in patients with neuroblastoma - Clare J. Twist
• Establishment of a reproducible methodology and results for molecular radiotherapy dosimetric assessment of ¹⁷⁷Lu-DOTATATE in neuroblastoma - Matthew D Aldridge
• An anti-O-acetylated GD2 ganglioside antibody for the immunotherapy of High – Grade Diffuse Glioma in children - Julien Fleurence
• Immunohistochemical evaluation of target expression in high-risk neuroblastoma samples to facilitate optimisation of molecular radiotherapy - Mark N Gaze
• Primary tumor resection after high dose chemotherapy with autologous hematopoietic stem cell transplantation is a safe and feasible option. A report from the Japanese neuroblastoma study group (JNBSG) - Tomoro Hishiki
• Opsoclonus-myoclonus syndrome in neuroblastoma: A report from the Japan Neuroblastoma Study Group (JNBSG) - Tomoko Iehara
• Combination therapy of highly activated natural killer cells and anti-disialoganglioside (GD2) antibody for Neuroblastoma: An experimental study - Minori MI Ishii
• Analysis of surgery for Neuroblastoma in The Netherlands - Merel Jans
• Low-risk neuroblastoma in Russia: therapy results and prognostic factors - Denis Kachanov
• Pharmacokinetics (PK) of 13-cis Retinoic Acid in COG Phase III Neuroblastoma Studies - Min H Kang
• Long term survival after KIR ligand incompatible allogeneic cord blood transplantation as a salvage therapy for relapsed stage IV neuroblastoma - Shinsuke Kataoka
• Treatment high-risk neuroblastoma. - Anatoly A P Kazantsev
• Prognostic Factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN Trial. - Ruth Ladenstein
• Primary tumour response to busulfan/melphalan high-dose chemotherapy in patients with high-risk neuroblastoma: a pilot study. - Daniel A Morgenstern
• Engraftment following busulfan/melphalan (BuMel) high-dose chemotherapy for high-risk neuroblastoma. A report from the HR-NBL-1/SIOPEN trial. - Daniel A Morgenstern
• Phase I study of anti-GD2 antibody ch14.18/CHO long term infusion in recurrent or refractory neuroblastoma patients in Japan - Atsushi Narita
• Complication of surgery for abdominal neuroblastoma: Chyle Leak   - Sajid Qureshi
• Expression, trafficking and biological significance of mitochondrial MRP1 in neuroblastoma. - Elizabeth Roundhill
• OMS/DES 2011 : a Multinational European Trial for Children with Opsoclonus Myoclonus Syndrome - Gudrun Schleiermacher
• Phase I trial of perifosine monotherapy in patients with relapsed or refractory neuroblastoma - Hiroyuki Shichino
• Generation of a new bicistronic DNA vaccine encoding for tyrosine hydroxylase and IL-15 to induce an active immune response against neuroblastoma - Nikolai Siebert
• Spinal canal invasion in peripheral neuroblastic tumors. Study design and preliminary results of a prospective SIOPEN Study Registry. - Stefania Sorrentino
• Creating Three-Dimensional full size model based on preoperative CT images for laparoscopic adrenalectomy and liver biopsy in a case demonstrating adrenal neuroblastoma with liver metastasis   - Ryota Souzaki
• 131Iodine-metaiodobenzylguanidine (131I -MIBG) and autologous stem cell transplantation harvesting and hematological reconstitution in high-risk neuroblastoma patients. - Godelieve Tytgat
• BEACON-2: design of a SIOPEN/ITCC multi-arm multi-stage (MAMS) trial for relapsed neuroblastoma - Keith Wheatley
• The role of image defined risk factor (IDRF) in evaluation of the risk of post-surgical kidneys dysfunction in children with neuroblastoma - Aleksandra Wieczorek
• Targeting activating transcription factor 5 (ATF5) in neuroblastoma with a novel dominant negative inhibitor - Darrell J Yamashiro
• A research of the induction and differentiation therapy for neuroblastioma in children - Jinhua Zhang
• Generation of new DNA- and protein vaccines for active immunotherapy against MYCN-expressing neuroblastoma - Maxi Zumpe
• Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma - Carmen Dorneburg
• Growth advantage and oncogene addiction of neuroblastoma cells bearing an ALK mutation - Simon Durand
• Impact of Neuroblastoma recurrent mutations on embryonic sympatho-adrenal development - Marco Gualandi
• Natural antibody against neuroblastoma of the TH-MYCN transgenic mice has CDC activity - Naonori Kawakubo
• MYCN Amplicon in Neuroblastoma (NB) Cell Lines - Venkatadri Kolla
• Identification of CASZ1 nuclear export signal (NES) reveals potential mechanism for loss of CASZ1 tumor suppressor activity in neuroblastoma (NB) - Zhihui Liu
• PPM1D/Wip1, the candidate gene on 17q contributing to neuroblastoma development - Jelena Milosevic
• Modulation of immune responses and radioresistance by neuroblastoma-derived and host-derived TrkB-target Galectin-1 - Katharina Batzke
• A non-canonical tumor suppression pathway identified in neuroblastoma – a new paradigm for personalized treatment and prognosis - Zhi Xiong Chen
• MYCN-induced miR-18a interferes with estrogen and NGF signaling to maintain an undifferentiated and more aggressive phenotype in neuroblastoma - Johanna Dzieran
• NPY/NPY5R copy number increases in relapsing neuroblastoma - Selene Elifio-Esposito
• MYCN-dependent regulation of gene expression during the cell cycle in neuroblastoma cells - Mona Friedrich
• The ABC transporter ABCE1 is a therapeutic target in neuroblastoma - Jixuan Gao
• The Poly (ADP-ribose) polymerase inhibitor olaparib causes mitotic catastrophe in MYCN amplified neuroblastoma by enhancing replication stress - Giuseppe Giannini
• Alternative lengthening of telomeres in primary neuroblastoma specimens – a genomic, epigenomic & proteomic approach - Sabine Hartlieb
• Characterisation of neuroblastoma cells isolated from bone marrow aspirates of children with stage 4 disease at diagnosis: an NCRI CCL CSG Neuroblastoma Group Study. - Charlotte Haunch-Smith
• PI3K and MAPK pathways mediate the BDNF/TrkB-increased migration and invasion in Neuroblastoma cells - Zhongyan Hua
• Inhibition of the growth factor midkine in neuroblastoma by an Okinawan agricultural product - Shinya Ikematsu
• Neuroblastoma: telomere elongation is responsible for aggressive behavior - Niloufar Javanmardi
• Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signalling and enhanced transendothelial migration - Maria Kavallaris
• Combination of HDAC and mitochondrial-targeted metabolism inhibitors exhibits strong therapeutic synergy in vitro and in vivo against neuroblastoma - Patrick Kim
• The involvement of Midkine, a growth factor exacerbating cisplatin-induced nephrotoxicity, in cisplatin resistance of neuroblastoma cells - Satoshi Kishida
• Identification of new synthetic lethal genes in MYCN-amplified neuroblastoma cells - Shinichi Kiyonari
• Suppression of Multidrug resistance protein 4 inhibits neuroblastoma growth both in vitro and in vivo - Jayne Murray
• MYCN mediates metabolic plasticity in childhood neuroblastoma - Ganna Oliynyk
• GOLPH3 regulates Golgi shape and is activated by DNA damage in neuroblastoma cell lines - Annalisa Pezzolo
• Patterns of PD-1, PD-L1 and PD-L2 Expression in Neuroblastoma - Navin Pinto
• Targeting fatty acid synthesis to induce neuroblastoma differentiation - María Victoria Ruiz Pérez
• Blinding the CYCLOPS – Neuroblastoma vulnerabilities unveiled by genomic loss - Alica Torkov
• Elevated expression of dyskerin is a potential therapeutic target with a telomerase-independent role in Myc/N-Myc-driven neuroblastoma - Sieu L Tran
• Epigenetic siRNA and chemosensitivity screens identify a vulnerability to SETD8 inhibition through reactivation of p53 canonical pathway in Neuroblastoma - Veronica Veschi
• The expression of AT Rich Interactive Domain 1A (ARID1A) in Neuroblastoma - My D Vu
• Integrative approach to define the cell surface landscape in neuroblastoma - Amber K Weiner
• Calreticulin-dependent VEGF expression promotes neuroblastoma differentiation - Pei-Yi Wu
• MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4 - Denise Yu
• Human stem cell models for relapse neuroblastoma - Tina Zheng